291 related articles for article (PubMed ID: 30131010)
1. Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis.
Navarria P; Pessina F; Cozzi L; Tomatis S; Reggiori G; Simonelli M; Santoro A; Clerici E; Franzese C; Carta G; Conti Nibali M; Bello L; Scorsetti M
Tumori; 2019 Feb; 105(1):47-54. PubMed ID: 30131010
[TBL] [Abstract][Full Text] [Related]
2. Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
Jackson WC; Tsien CI; Junck L; Leung D; Hervey-Jumper S; Orringer D; Heth J; Wahl DR; Spratt DE; Cao Y; Lawrence TS; Kim MM
J Neurooncol; 2018 May; 138(1):155-162. PubMed ID: 29388034
[TBL] [Abstract][Full Text] [Related]
3. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial.
Pedretti S; Masini L; Turco E; Triggiani L; Krengli M; Meduri B; Pirtoli L; Borghetti P; Pegurri L; Riva N; Gatta R; Fusco V; Scoccianti S; Bruni A; Ricardi U; Santoni R; Magrini SM; Buglione M
J Neurooncol; 2019 Jul; 143(3):447-455. PubMed ID: 31054101
[TBL] [Abstract][Full Text] [Related]
7. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
Biau J; Chautard E; De Schlichting E; Dupic G; Pereira B; Fogli A; Müller-Barthélémy M; Dalloz P; Khalil T; Dillies AF; Durando X; Godfraind C; Verrelle P
Radiat Oncol; 2017 Dec; 12(1):197. PubMed ID: 29212499
[TBL] [Abstract][Full Text] [Related]
9. Feasibility evaluation of hypofractionated radiotherapy with concurrent temozolomide in elderly patients with glioblastoma.
Uto M; Mizowaki T; Ogura K; Arakawa Y; Mineharu Y; Miyamoto S; Hiraoka M
Int J Clin Oncol; 2016 Dec; 21(6):1023-1029. PubMed ID: 27384182
[TBL] [Abstract][Full Text] [Related]
10. Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study.
Navarria P; Pessina F; Tomatis S; Soffietti R; Grimaldi M; Lopci E; Chiti A; Leonetti A; Casarotti A; Rossi M; Cozzi L; Ascolese AM; Simonelli M; Marcheselli S; Santoro A; Clerici E; Bello L; Scorsetti M
Oncotarget; 2017 Sep; 8(40):67696-67708. PubMed ID: 28978064
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of hypofractionated radiotherapy (HFRT) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: A meta-analysis.
Guo L; Li X; Chen Y; Liu R; Ren C; Du S
Cancer Radiother; 2021 Apr; 25(2):182-190. PubMed ID: 33436285
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.
Jablonska PA; Diez-Valle R; Pérez-Larraya JG; Moreno-Jiménez M; Idoate MÁ; Arbea L; Tejada S; Garcia de Eulate MR; Ramos L; Arbizu J; Domínguez P; Aristu JJ
PLoS One; 2019; 14(6):e0217881. PubMed ID: 31170245
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis.
Navarria P; Pessina F; Franzese C; Tomatis S; Perrino M; Cozzi L; Simonelli M; Bello L; Clerici E; Riva M; Santoro A; Scorsetti M
Radiother Oncol; 2018 Apr; 127(1):108-113. PubMed ID: 29291951
[TBL] [Abstract][Full Text] [Related]
14. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
Shenouda G; Souhami L; Petrecca K; Owen S; Panet-Raymond V; Guiot MC; Corredor AG; Abdulkarim B
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):487-494. PubMed ID: 28011051
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Malmström A; Grønberg BH; Marosi C; Stupp R; Frappaz D; Schultz H; Abacioglu U; Tavelin B; Lhermitte B; Hegi ME; Rosell J; Henriksson R;
Lancet Oncol; 2012 Sep; 13(9):916-26. PubMed ID: 22877848
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
[TBL] [Abstract][Full Text] [Related]
17. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
[TBL] [Abstract][Full Text] [Related]
20. Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma.
Yusuf M; Ugiliweneza B; Amsbaugh M; Boakye M; Williams B; Nelson M; Hattab EM; Woo S; Burton E
Oncology; 2018; 95(1):39-42. PubMed ID: 29694955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
